Congenital Hyperinsulinism Treatment Market is Estimated to Witness High Growth

Congenital hyperinsulinism (CHI) is a genetic disorder affecting infants and children and characterized by inappropriate and excessive insulin secretion by pancreatic beta cells. It leads to recurrent episodes of low blood sugar (hypoglycemia) and other serious health issues if not treated on time. The global market for congenital hyperinsulinism treatment is dominated by medicines such as diazoxide and somatostatin analog injections. Surgery is also a treatment option for patients with severe and uncontrollable hypoglycemia.

The global congenital hyperinsulinism treatment market is estimated to be valued at US$ 217.74 Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
One of the key drivers for the growth of the congenital hyperinsulinism treatment market is the increasing prevalence of CHI disorder globally. According to some estimates, around 1 in 40,000 newborns is affected by CHI. The condition is more common in people of Ashkenazi Jewish and Finnish descent. The rising cases of CHI is driving the demand for effective treatment options like diazoxide, somatostatin analog injections, and surgery in severe cases. Diazoxide is the most widely used first line treatment drug for CHI. Its sales have been rising over the recent years owing to growing adoption for congenital hyperinsulinism. Somatostatin analog injections like octreotide are also gaining popularity for treating refractory CHI cases that do not respond to diazoxide. The availability of various treatment alternatives and growing disease prevalence are fueling the overall growth of the market during the forecast period.

SWOT Analysis

Strength: The congenital hyperinsulinism treatment market is growing due to rising incidences of congenital hyperinsulinism around the world. Growing awareness about screening and diagnosis is also supporting market growth. Advances in surgical techniques and medical devices for treatment are fueling adoption.

Weakness: High costs associated with treatment procedures and devices pose a major challenge. Management of severe cases is difficult and requires lifelong care and monitoring. Lack of expertise and facilities especially in developing nations hinders market expansion.

Opportunity: Untapped potential in developing countries presents lucrative opportunities. Research on newer drugs and medical devices can provide novel treatment options. Developing affordable treatment alternatives can boost accessibility in price-sensitive markets.

Threats: Low diagnosis rates in low-income countries limits the addressable market. Risks of recurrence and complications post-surgery hamper procedures' popularity. Lack of treatment guidelines and protocols pose threats.

Key Takeaways

The Global Congenital Hyperinsulinism Treatment Market Size is expected to witness high growth in the forecast period. The market size is projected to reach US$ 217.74 Mn by 2024 from US$ 149 Mn in 2020, registering a CAGR of 6.2%.

Regional analysis: North America currently dominates the market owing to high diagnosis rates and availability of advanced treatment options. However, Asia Pacific is emerging as the fastest growing region on back of rising healthcare spending, increasing patient volumes, and improving medical infrastructure.

Key players: Key players operating in the congenital hyperinsulinism treatment market are Medtronic, Ace-medical, VOGT MEDICAL, BD (Becton, Dickinson and Company), Smiths Medical, Inc., Samtronic., CODAN ARGUS AG, B. Braun SE, Medical Components, Inc., Fresenius SE & Co. KGaA, Baxter, EuroLife Healthcare Pvt. Ltd, and Micrel Medical Devices. Medtronic and BD together hold over 50% share due to their broad portfolio of medical devices for surgical treatment of congenital hyperinsulinism.